Subscribe

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

NEW INDICATIONS

Keytruda plus Chemotherapy FDA Approved for First-Line Treatment of Cervical Cancer

JHOP - December 2021 Vol 11, No 6 - FDA Oncology Update
Download PDF

On October 13, 2021, the FDA accelerated the approval of pembrolizumab (Keytruda; Merck), in combination with chemotherapy, with or without bevacizumab (Avastin), for the treatment of patients with persistent, recurrent, or metastatic cervical cancer who have not received chemotherapy and whose tumors express PD-L1 ≥1%, as determined by an FDA-approved test.

At the same time, the FDA also granted regular approval to pembrolizumab as a single agent for patients with recurrent or metastatic cervical cancer whose disease progressed during or after chemotherapy and PD-L1 expression ≥1%, as determined by an FDA-approved test. In June 2018, the FDA accelerated the approval of this indication to pembrolizumab.

The approval of first-line pembrolizumab plus chemotherapy indication was based on the KEYNOTE-826 study, a multicenter, randomized, double-blind, placebo-controlled clinical trial. The study included 617 patients with persistent, recurrent, or first-line metastatic cervical cancer who had not received chemotherapy. Patients were enrolled regardless of a PD-L1 expression status. Patients were randomized in a 1:1 ratio to pembrolizumab plus paclitaxel and cisplatin or paclitaxel and carboplatin, with or without bevacizumab, or to placebo plus chemotherapy, with or without bevacizumab. Pembrolizumab therapy continued until disease progression, unacceptable adverse events, or completion of 24-month treatment.

The main efficacy measures were overall survival (OS) and progression-free survival (PFS). Secondary measures were objective response rate (ORR) and duration of response (DOR).

For the 548 patients with tumors expressing PD-L1 ≥1%, the median OS was not reached (NR; 95% confidence interval [CI], 19.8-NR) in the pembrolizumab arm versus 16.3 months (95% CI, 14.5-19.4) in the placebo arm (hazard ratio [HR], 0.64; 95% CI, 0.50-0.81; 1-sided P = .0001). The median PFS was 10.4 months (95% CI, 9.7-12.3) in the pembrolizumab arm and 8.2 months (95% CI, 6.3-8.5) in the placebo arm (HR, 0.62; 95% CI, 0.50-0.77; 1-sided P <.0001). The ORR was 68% and 50%, and the median DOR was 18 months and 10.4 months, respectively.

The most common (≥20%) adverse reactions in the pembrolizumab arm were peripheral neuropathy, alopecia, anemia, fatigue/asthenia, nausea, neutropenia, diarrhea, hypertension, thrombocytopenia, constipation, arthralgia, vomiting, urinary tract infection, rash, leukopenia, hypothyroidism, and decreased appetite.

Related Items
Lytgobi FDA Approved for Intrahepatic Cholangiocarcinoma with FGFR2 Fusion
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Vegzelma a New Biosimilar FDA Approved for the Treatment of 6 Types of Cancer
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Pedmark First Drug Approved for Hearing Loss Prevention in Children with Solid Tumors
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Retevmo Receives New FDA Indication for Advanced Solid Tumors with RET Fusion
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Imfinzi Receives New FDA Indication for Advanced or Metastatic Biliary Tract Cancer
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Pemazyre Receives New Indication for FGFR1-­Positive Myeloid/Lymphoid Neoplasms
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Imbruvica Now Also Indicated for Children with Chronic Graft-versus-Host Disease
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Enhertu First FDA-Approved Drug for HER2-Positive Non–Small-Cell Lung Cancer
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Enhertu First FDA-Approved Treatment for HER2-Low Breast Cancer
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Nubeqa Now Indicated for Metastatic Hormone-Sensitive Prostate Cancer
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.